Stoke Therapeutics, Inc. Initial Public Offering

Davis Polk advised the representatives of the underwriters in connection with the $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc., which includes 1,183,666 shares from the full exercise of the underwriters’ over-allotment option to purchase additional shares. Stoke Therapeutics, Inc. is listed on the Nasdaq Global Select Market under the symbol “STOK.”

Based in Cambridge, Massachusetts, Stoke Therapeutics is a biotechnology company that is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health.

The Davis Polk capital markets team included partner Deanna L. Kirkpatrick and associates Jennifer Ying Lan, Ariel Rivera and Meaghan Kennedy. Partner David R. Bauer and associate Michael V. Policastro provided intellectual property and technology advice. The tax team included partner Michael Mollerus and associate Dao Fu. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.